Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Absence of effect of the antiretrovirals Duovir and Viraday on mitochondrial bioenergetics.

Fadel JJ, Bahr GM, Echtay KS.

J Cell Biochem. 2018 Dec;119(12):10384-10392. doi: 10.1002/jcb.27384. Epub 2018 Sep 6.

PMID:
30187948
2.

Defining Genome-Wide Expression and Phenotypic Contextual Cues in Macrophages Generated by Granulocyte/Macrophage Colony-Stimulating Factor, Macrophage Colony-Stimulating Factor, and Heat-Killed Mycobacteria.

Bazzi S, El-Darzi E, McDowell T, Modjtahedi H, Mudan S, Achkar M, Akle C, Kadara H, Bahr GM.

Front Immunol. 2017 Oct 3;8:1253. doi: 10.3389/fimmu.2017.01253. eCollection 2017.

3.

Immunomodulatory effects of heat-killed Mycobacterium obuense on human blood dendritic cells.

Bazzi S, Modjtahedi H, Mudan S, Achkar M, Akle C, Bahr GM.

Innate Immun. 2017 Oct;23(7):592-605. doi: 10.1177/1753425917727838. Epub 2017 Aug 30.

PMID:
28853313
4.

Differential regulation of surface receptor expression, proliferation, and apoptosis in HaCaT cells stimulated with interferon-γ, interleukin-4, tumor necrosis factor-α, or muramyl dipeptide.

El Darzi E, Bazzi S, Daoud S, Echtay KS, Bahr GM.

Int J Immunopathol Pharmacol. 2017 Jun;30(2):130-145. doi: 10.1177/0394632017707611. Epub 2017 Apr 28.

5.

Analysis of the immunomodulatory properties of two heat-killed mycobacterial preparations in a human whole blood model.

Bazzi S, Modjtahedi H, Mudan S, Akle C, Bahr GM.

Immunobiology. 2015 Dec;220(12):1293-304. doi: 10.1016/j.imbio.2015.07.015. Epub 2015 Jul 26.

PMID:
26253276
6.

Lopimune-induced mitochondrial toxicity is attenuated by increased uncoupling protein-2 level in treated mouse hepatocytes.

El Hoss S, Bahr GM, Echtay KS.

Biochem J. 2015 Jun 15;468(3):401-7. doi: 10.1042/BJ20150195. Epub 2015 Apr 13.

PMID:
26173235
7.

Identification of a synthetic muramyl peptide derivative with enhanced Nod2 stimulatory capacity.

Rubino SJ, Magalhaes JG, Philpott D, Bahr GM, Blanot D, Girardin SE.

Innate Immun. 2013 Oct;19(5):493-503. doi: 10.1177/1753425912471691. Epub 2013 Jan 22.

PMID:
23339926
8.
9.

Effect of muramyl peptides on mitochondrial respiration.

El-Jamal N, Bahr GM, Echtay KS.

Clin Exp Immunol. 2009 Jan;155(1):72-8. doi: 10.1111/j.1365-2249.2008.03794.x.

10.

Up-regulation of NOD1 and NOD2 through TLR4 and TNF-alpha in LPS-treated murine macrophages.

Takahashi Y, Isuzugawa K, Murase Y, Imai M, Yamamoto S, Iizuka M, Akira S, Bahr GM, Momotani E, Hori M, Ozaki H, Imakawa K.

J Vet Med Sci. 2006 May;68(5):471-8.

11.

Immune deficiency in HIV-1 infection: novel therapeutic approaches targeting innate and adaptive responses.

Bahr GM.

Expert Rev Clin Immunol. 2005 Nov;1(4):529-47. doi: 10.1586/1744666X.1.4.529.

PMID:
20477596
12.
13.

A novel cellular RNA helicase, RH116, differentially regulates cell growth, programmed cell death and human immunodeficiency virus type 1 replication.

Cocude C, Truong MJ, Billaut-Mulot O, Delsart V, Darcissac E, Capron A, Mouton Y, Bahr GM.

J Gen Virol. 2003 Dec;84(Pt 12):3215-25.

PMID:
14645903
14.

A phase I study of a six-week cycle of immunotherapy with Murabutide in HIV-1 patients naive to antiretrovirals.

De La Tribonniere X, Mouton Y, Vidal V, Darcissac E, Sissoko D, Fontier C, Douadi Y, Dewulf Jl, Amiel C, Bahr GM.

Med Sci Monit. 2003 Jun;9(6):PI43-50.

PMID:
12824957
15.

Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment.

Bahr GM, De La Tribonniere X, Darcissac E, Ajana F, Bocket L, Sissoko D, Yazdanpanah Y, Dewulf J, Amiel C, Mouton Y.

J Antimicrob Chemother. 2003 Jun;51(6):1377-88. Epub 2003 Apr 25.

PMID:
12716777
17.

Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide.

Bahr GM.

J Antimicrob Chemother. 2003 Jan;51(1):5-8. Review. No abstract available.

PMID:
12493780
18.

Clinical tolerance and immunologic effects after single or repeated administrations of the synthetic immunomodulator murabutide in HIV-1-infected patients.

Amiel C, De La Tribonnière X, Vidal V, Darcissac E, Mouton Y, Bahr GM.

J Acquir Immune Defic Syndr. 2002 Jul 1;30(3):294-305.

PMID:
12131566
19.
20.
21.
22.

SS-56, a novel cellular target of autoantibody responses in Sjögren syndrome and systemic lupus erythematosus.

Billaut-Mulot O, Cocude C, Kolesnitchenko V, Truong MJ, Chan EK, Hachula E, de la Tribonnière X, Capron A, Bahr GM.

J Clin Invest. 2001 Sep;108(6):861-9.

25.

Selective regulation of human immunodeficiency virus-infected CD4(+) lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice.

Bahr GM, Darcissac EC, Castéran N, Amiel C, Cocude C, Truong MJ, Dewulf J, Capron A, Mouton Y.

J Virol. 2001 Aug;75(15):6941-52.

26.

Modulation of cellular and humoral immune responses to a multiepitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boost.

Billaut-Mulot O, Idziorek T, Loyens M, Capron A, Bahr GM.

Vaccine. 2001 Apr 6;19(20-22):2803-11.

PMID:
11282190
27.

Cytokine analysis at the single cell level and lymphoproliferative responses to mycobacterial antigens in HIV-1 patients with successful virologic response to potent antiretrovirals.

Amiel C, Kusnierz JP, Mouton Y, Rook G, Stanford J, Singh M, Capron A, Bahr GM.

J Clin Immunol. 2000 Nov;20(6):458-65.

PMID:
11202236
28.
29.

Interleukin-18 modulates immune responses induced by HIV-1 Nef DNA prime/protein boost vaccine.

Billaut-Mulot O, Idziorek T, Ban E, Kremer L, Dupré L, Loyens M, Riveau G, Locht C, Capron A, Bahr GM.

Vaccine. 2000 Aug 15;19(1):95-102.

PMID:
10924791
30.
31.
32.

Interleukin-16 inhibits human immunodeficiency virus type 1 entry and replication in macrophages and in dendritic cells.

Truong MJ, Darcissac EC, Hermann E, Dewulf J, Capron A, Bahr GM.

J Virol. 1999 Aug;73(8):7008-13.

33.

Interleukin-16 (IL-16) inhibits human immunodeficiency virus replication in cells from infected subjects, and serum IL-16 levels drop with disease progression.

Amiel C, Darcissac E, Truong MJ, Dewulf J, Loyens M, Mouton Y, Capron A, Bahr GM.

J Infect Dis. 1999 Jan;179(1):83-91.

PMID:
9841826
34.

Molecular modeling of HIV-1 coreceptor CCR5 and exploring of conformational space of its extracellular domain in molecular dynamics simulation.

Efremov RG, Legret F, Vergoten G, Capron A, Bahr GM, Arseniev AS.

J Biomol Struct Dyn. 1998 Aug;16(1):77-90.

PMID:
9745897
36.

Recombinant human IL-16 inhibits HIV-1 replication and protects against activation-induced cell death (AICD).

Idziorek T, Khalife J, Billaut-Mulot O, Hermann E, Aumercier M, Mouton Y, Capron A, Bahr GM.

Clin Exp Immunol. 1998 Apr;112(1):84-91.

37.

Elevated serum level of Fas ligand correlates with the asymptomatic stage of human immunodeficiency virus infection.

Bahr GM, Capron A, Dewulf J, Nagata S, Tanaka M, Bourez JM, Mouton Y.

Blood. 1997 Jul 15;90(2):896-8. No abstract available.

38.

Role of nitric oxide in the regulation of lymphocyte apoptosis and HIV-1 replication.

Hermann E, Idziorek T, Kusnierz JP, Mouton Y, Capron A, Bahr GM.

Int J Immunopharmacol. 1997 Jul;19(7):387-97.

PMID:
9568543
39.

Suppression of in vivo IgE and tissue IL-4 mRNA induction by SDZ 280.636, a synthetic muramyl dipeptide derivative.

Kricek F, Zunic M, Ruf C, De Jong G, Dukor P, Bahr GM.

Immunopharmacology. 1997 Apr;36(1):27-39.

PMID:
9129994
40.

Selective potentiation of cytokine expression in human whole blood by murabutide, a muramyl dipeptide analogue.

Darcissac EC, Bahr GM, Pouillart PR, Riveau GJ, Parant MA.

Cytokine. 1996 Aug;8(8):658-66.

PMID:
8894442
41.

Selective induction of CD11a,b,c/CD18 and CD54 expression at the cell surface of human leukocytes by muramyl peptides.

Darcissac EC, Bahr GM, Parant MA, Chedid LA, Riveau GJ.

Cell Immunol. 1996 May 1;169(2):294-301.

PMID:
8620558
42.

Modulation of expression of class II MHC and CD40 molecules in murine B cells by various muramyl dipeptides.

Cohen LY, Bahr GM, Darcissac EC, Parant MA.

Cell Immunol. 1996 Apr 10;169(1):75-84.

PMID:
8612298
43.
44.

Enhancement by muramyl peptides of the protective response of interferon-alpha/beta against encephalomyocarditis virus infection.

Pouillart PR, Audibert FM, Chedid LA, Lefrancier PL, Bahr GM.

Int J Immunopharmacol. 1996 Mar;18(3):183-92.

PMID:
8796446
46.
47.
48.

Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on murabutide.

Bahr GM, Darcissac E, Bevec D, Dukor P, Chedid L.

Int J Immunopharmacol. 1995 Feb;17(2):117-31.

PMID:
7544767
49.

Selective modulation of lipopolysaccharide-induced death and cytokine production by various muramyl peptides.

Parant MA, Pouillart P, Le Contel C, Parant FJ, Chedid LA, Bahr GM.

Infect Immun. 1995 Jan;63(1):110-5.

50.

Detection of intestinal flora-derived bacterial antigen complexes in splenic macrophages of rats.

Kool J, De Visser H, Gerrits-Boeye MY, Klasen IS, Melief MJ, Van Helden-Meeuwsen CG, Van Lieshout LM, Ruseler-Van Embden JG, Van den Berg WB, Bahr GM, et al.

J Histochem Cytochem. 1994 Nov;42(11):1435-41.

PMID:
7930525

Supplemental Content

Support Center